[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100471807":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":7,"responsibleParty":17,"collaborators":7,"id":19,"slug":20,"hasResults":21,"nctId":22,"briefTitle":23,"officialTitle":24,"acronym":7,"eligibilityCriteria":25,"healthyVolunteers":21,"sex":26,"minAge":27,"maxAge":7,"enrollmentInfo":28,"targetDuration":7,"studyType":31,"phases":7,"briefSummary":32,"conditions":33,"keywords":36,"overallStatus":41,"whyStopped":7,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":7},{"fullName":5,"class":6},"Power Life Sciences Inc.","INDUSTRY",null,[9],{"name":10,"affiliation":5,"role":11},"Michael B Gill","STUDY_DIRECTOR",[13],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},"CONTACT","415-900-4227","https:\u002F\u002Fwww.withpower.com\u002Fcontact-us@withpower.com",{"type":18,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100471807","clinical-trial---analyzing-participation-experiences-of-amyotrophic-lateral-sclerosis-patients-100471807",false,"NCT05423678","Clinical Trial - Analyzing Participation Experiences Of Amyotrophic Lateral Sclerosis Patients","In Depth Observational Clinical Trial - Analyzing Participation Experiences Of Amyotrophic Lateral Sclerosis Patients","Inclusion Criteria:\n\n* Lives in the United States\n* Is 18+ years old\n* Participant has a diagnosis of Amyotrophic Lateral Sclerosis (ALS)\n* Participant has enrolled in an interventional clinical for ALS (self-reported)\n\nExclusion Criteria\n\n* Inability to perform regular electronic reporting\n* Patient does not understand, sign, and return consent form\n* No diagnosis of Amyotrophic Lateral Sclerosis (ALS) confirmed","ALL","18 Years",{"count":29,"type":30},500,"ESTIMATED","OBSERVATIONAL","Clinical trial participation has always been substantially skewed toward certain demographic groups. However, there has been little study on whether trial qualities impact participation in either a positive or negative way. The goal of this research is to identify the characteristics that consistently restrict patients' ability to participate in or complete a trial in which they were initially interested. This data will be analyzed via a number of demographic lenses in order to find trends that could benefit future ALS sufferers.",[34,35],"ALS","Amyotrophic Lateral Sclerosis",[37,38,39,40],"als","als clinical trials","als diversity studies","amyotrophic lateral sclerosis","NOT_YET_RECRUITING","2023-12-29",{"date":44,"type":45},"2024-01-02","ACTUAL",{"date":47,"type":30},"2024-07",{"date":49,"type":30},"2026-07",{"name":5,"class":6}]